Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up

Belal Aljabri; Wolfgang Lilleby; Marta D Switlyk; Gunnar Tafjord

doi:10.1016/j.eucr.2021.101648

Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up

Urol Case Rep. 2021 Mar 23:37:101648. doi: 10.1016/j.eucr.2021.101648. eCollection 2021 Jul.

Authors

Belal Aljabri^{1

2}, Wolfgang Lilleby¹, Marta D Switlyk³, Gunnar Tafjord¹

Affiliations

¹ Department of Oncology, The Norwegian Radiumhospitalet, Oslo University Hospital, Oslo, Norway.
² Department of Palliative medicine, Akershus University Hospital, Lørenskog, Norway.
³ Department of Radiology, The Norwegian Radiumhospitalet, Oslo University Hospital, Oslo, Norway.

Abstract

Pituitary apoplexy is a clinical syndrome caused by hemorrhage or infarction of a pituitary adenoma. There have been a few reports in the literature of rapid onset of pituitary apoplexy after goserelin injection. To the best of our knowledge, there is no publication in the literature reporting re-introducing goserelin therapy for patients with prostate cancer after the onset of pituitary apoplexy. In this case report, we present the onset and clinico-radiological course of pituitary apoplexy induced by the initiation of goserelin and during continuation of goserelin with up to five-years follow-up.

Keywords: Gonadotropin releasing hormone; Goserelin; Pituitary apoplexy; Prostate cancer.

Publication types

Case Reports